CN111825615B - Oxidized isoaporphine alkaloid derivative and application thereof - Google Patents

Oxidized isoaporphine alkaloid derivative and application thereof Download PDF

Info

Publication number
CN111825615B
CN111825615B CN202010706122.8A CN202010706122A CN111825615B CN 111825615 B CN111825615 B CN 111825615B CN 202010706122 A CN202010706122 A CN 202010706122A CN 111825615 B CN111825615 B CN 111825615B
Authority
CN
China
Prior art keywords
oxidized
isoaporphine
azabenzanthrone
compound
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010706122.8A
Other languages
Chinese (zh)
Other versions
CN111825615A (en
Inventor
孙建博
张佳瑶
王豫锦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
China Pharmaceutical University
Original Assignee
China Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by China Pharmaceutical University filed Critical China Pharmaceutical University
Priority to CN202010706122.8A priority Critical patent/CN111825615B/en
Publication of CN111825615A publication Critical patent/CN111825615A/en
Application granted granted Critical
Publication of CN111825615B publication Critical patent/CN111825615B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses an oxidized isoaporphine derivative shown as a formula I, wherein R is shown as
Figure DDA0002594813200000011
A is selected from-O-or a covalent bond, n is an integer of 0-4, R1Is selected from
Figure DDA0002594813200000012
Figure DDA0002594813200000013
‑NR2R3；R2Selected from H, R3A linear or branched alkyl selected from C1-C3; with the proviso that A is selected from-O-, n ═ 2, 3, R1Is selected from
Figure DDA0002594813200000014
Compared with the oxidized isoaporphine, the oxidized isoaporphine alkaloid derivative has obviously improved inhibitory activity and solubility on lung cancer, liver cancer and breast cancer. The invention also discloses the application of the oxidized isoaporphine derivative in preparing antitumor drugs.

Description

Oxidized isoaporphine alkaloid derivative and application thereof
Technical Field
The invention belongs to the field of medicinal chemistry and pharmacotherapeutics, and particularly relates to an oxidized isoaporphine alkaloid derivative, a preparation method thereof and application of the novel compound in preparing anti-cancer medicaments.
Background
Cancer is a major disease affecting human health and life, and has become one of the major public health problems worldwide. According to the global cancer report, 1810 ten thousands of cancer cases are predicted to be newly added in 2018 all over the world, the number of deaths reaches 960 ten thousands, the global cancer burden is further increased, and more people pay attention to the treatment of cancer. The natural product is a treasure house for finding novel antitumor drugs, various natural products are proved to have antitumor activity at present, but the natural products often have the problems of toxic and side effects, solubility, stability and the like, and the natural products need to be structurally modified to become the antitumor drugs which can be clinically used.
Oxoisoaporphine alkaloids (Oxoisoaporphine) refer to isoquinoline alkaloids containing 1-azabenzanthrone (1-azabenzanthrone) skeleton. It was originally isolated from Menispermum dauricum DC (Menispermum dauricum DC) belonging to Menispermum of Menispermaceae. In recent years, the antitumor activity of the oxidized isoaporphine alkaloid draws attention, and researches show that the skeleton 1 of the oxidized isoaporphine alkaloid can be embedded into a double-helix structure of DNA through pi-pi accumulation so as to induce the generation of an apoptosis mechanism; inhibiting topoisomerase to affect cell proliferation, and further showing antitumor activity.
The oxidized isoaporphine alkaloid and the derivative thereof are expected to become novel high-efficiency antitumor drugs. The activity of such alkaloids can be significantly improved by appropriate side chain introduction.
Disclosure of Invention
The invention aims to select the common parent ring-1-azabenzanthrone of the oxidized isoaporphine alkaloid as a guide substance to carry out structural modification on the C-4 position, thereby obtaining a series of oxidized isoaporphine alkaloid derivatives with obviously improved activity and increased solubility compared with the oxidized isoaporphine.
The purpose of the invention is realized by the following technical scheme:
an oxidized isoaporphine derivative represented by formula I:
Figure BDA0002594813190000011
wherein R is as
Figure BDA0002594813190000012
A is selected from-O-or a covalent bond, n is an integer of 0-4, R1Is selected from
Figure BDA0002594813190000013
Figure BDA0002594813190000021
-NR2R3；R2Selected from H, R3A linear or branched alkyl selected from C1-C3; with the proviso that A is selected from the group consisting of-O-, n-2, 3, R1Is selected from
Figure BDA0002594813190000022
Preferably, A is selected from-O-, n is an integer of 2-4, and R is1Is selected from
Figure BDA0002594813190000023
Figure BDA0002594813190000024
But not including n 2, 3, R1Is selected from
Figure BDA0002594813190000025
Or A is selected from covalent bond, n is 0, R1Is selected from
Figure BDA0002594813190000026
More preferably, a is selected from-O-, n ═ 2, and R1Is selected from
Figure BDA0002594813190000027
Figure BDA0002594813190000028
In particular, the compound of formula I is selected from the following compounds:
4- [ (2-morpholine) ethoxy ] -1-azabenzanthrone; 4- [ (2-isopropylamino) ethoxy ] -1-azabenzanthrone; 4- [2- (2-methylpiperidine) ethoxy ] -1-azabenzanthrone; 4- [2- (4-hydroxyethylpiperazine) ethoxy ] -1-azabenzanthrone; 4- [ (3-morpholine) propoxy ] -1-azabenzanthrone; 4- [3- (2-methylpiperidine) propoxy ] -1-azabenzanthrone; 4- [4- (2-methylpiperidine) butoxy ] -1-azabenzanthrone; 4- [ (4-morpholine) butoxy ] -1-azabenzanthrone; 4- [ (4-isopropylamino) butoxy ] -1-azabenzanthrone; 4- [4- (4-methylpiperazine) butoxy ] -1-azabenzanthrone; 4- [4- (4-hydroxyethylpiperazine) butoxy ] -1-azabenzanthrone; 4-piperazine-1-azabenzanthrone.
The invention also aims to provide a preparation method of the oxidized isoaporphine derivative shown as the formula I,
when A is selected from-O-, n is an integer of 2-4, R1Is selected from
Figure BDA0002594813190000029
Figure BDA00025948131900000210
But not including n 2, 3, R1Is selected from
Figure BDA00025948131900000211
The reaction scheme is as follows:
Figure BDA00025948131900000212
the method comprises the following steps:
dissolving 1-azabenzanthrone in diethylene glycol, providing a strong alkali environment with sodium hydroxide, and carrying out hydroxylation reaction with hydrazine hydrate to generate 4-hydroxy-1-azabenzanthrone;
step (2), taking 4-hydroxy-1-azabenzanthrone as a raw material, and reacting with a compound shown in the formula
Figure BDA0002594813190000031
Reacting the dibromoalkane to obtain an intermediate; in the presence of potassium carbonate andreacting the intermediate with a compound of formula R in the presence of catalytic amount of CTAB catalyst1And (3) reacting secondary amine shown as H to obtain the oxidized isoaporphine derivative.
In the step (2), the solvent adopted is one or more selected from DMF, acetone, acetonitrile, toluene, benzene, xylene, 1, 4-dioxane, ethyl acetate, dichloromethane, chloroform, tetrahydrofuran or diethyl ether.
The molar ratio of the 4-hydroxy-1-azabenzanthrone to the potassium carbonate to the dibromoalkane is 1:1.5: 1; the reaction temperature is 0-80 ℃.
The molar ratio of the intermediate to potassium carbonate to secondary amine is 1:1.5: 1.2; the reaction temperature is 0-60 ℃.
When A is selected from covalent bond, n is 0, R1Is selected from
Figure BDA0002594813190000032
The reaction scheme is as follows:
Figure BDA0002594813190000033
the preparation method of the oxidized isoaporphine derivative has mild reaction conditions, low toxicity of the used reagent, easily obtained raw materials, convenient post-treatment and higher yield.
The oxidized iso-aporphine alkaloid derivative has excellent antitumor activity on lung cancer cell strains A549, liver cancer cells HepG-2, human breast cancer cell strains McF-7, MDA-MB-231 and adriamycin-resistant cell strains McF-7/ADR, and the activity is obviously improved compared with the oxidized iso-aporphine. Therefore, the invention also aims to provide the application of the oxidized isoaporphine alkaloid derivative shown as the formula I in preparing the antitumor drugs.
The tumor is lung cancer, liver cancer and breast cancer.
Detailed description of the preferred embodiments
To further illustrate the invention, a series of examples are set forth below. These examples are illustrative and should not be construed as limiting the invention.
Example 1: 4- [ (2-morpholine) ethoxy]-1-azabenzoylAnthracene ketone (I)1) Synthesis of (2)
The reaction formula is as follows:
Figure BDA0002594813190000034
4-hydroxy-1-azabenzanthrone (1eq) was dissolved in 5mL of anhydrous DMF and K was added2CO3(1.5eq) and 1, 2-dibromoethane (1eq), stirring at 80 ℃ overnight to stop the reaction, adding ethyl acetate and saturated brine into the reaction solution to extract DMF, purifying by silica gel column chromatography (eluent is petroleum ether: ethyl acetate P/E ═ 3:1) to obtain intermediate 4- (2-bromoethoxy) -1-azabenzanthrone, adding 4- (2-bromoethoxy) -1-azabenzanthrone (1eq) into the reaction flask, dissolving with 5mL of anhydrous DMF, adding K2CO3(1.5eq), CTAB and morpholine (1.2eq) at 60 ℃ overnight with stirring, stopping the reaction, extracting to remove DMF, and purifying by silica gel column chromatography (eluent petroleum ether: ethyl acetate P/E: 5:1) to give compound I1Yellow solid, yield 67%. Compound I1Identified as 4- [ (2-morpholine) ethoxy]-1-azabenzanthrone.
ESI-MS：360.4.[M+H]+。
1H-NMR(300MHz,CDCl3,ppm),δH 8.92(d,J＝6Hz,1H),8.78(d,J＝6Hz,1H),8.64(d,J＝9Hz,1H),8.44(d,J＝6Hz,1H),8.04(d,J＝6Hz,1H),7.81(t,J＝9Hz,1H),7.69(t,J＝9Hz,1H),7.16(d,J＝9Hz,1H),4.42(d,J＝6Hz,2H),3.78(4H,s),3.02(t,J＝6Hz,2H),2.70(4H,s).
Example 2: compound 4- [ (2-isopropylamino) ethoxy]-1-azabenzanthrone (I)2) Synthesis of (2)
The reaction formula is as follows:
Figure BDA0002594813190000041
reference Compound I1The preparation method comprises replacing compound morpholine with isopropylamine, and obtaining the target compound I under the same conditions2Yellow solid, 58% yield. Compound (I)I2Identified as 4- [ (2-isopropylamino) ethoxy]-1-azabenzanthrone.
ESI-MS：333.2.[M+H]+。
1H-NMR(300MHz,CDCl3,ppm),δH 8.86(d,J＝9Hz,1H),8.77(d,J＝6Hz,1H),8.48(d,J＝9Hz,1H),8.28(d,J＝9Hz,1H),7.98(d,J＝6Hz,1H),7.87(t,J＝7.5Hz,1H)，7.73(t,J＝7.5Hz,1H),7.60(d,J＝9Hz,1H),4.6(s,1H)，3.96(t,J＝6Hz,2H),3.45(s,3H),1.24(d,J＝6Hz,6H).
Example 3: 4- [2- (2-methylpiperidine) ethoxy]-1-azabenzanthrone (I)3) Synthesis of (2)
The reaction formula is as follows:
Figure BDA0002594813190000042
reference Compound I1The target compound I is prepared by replacing compound morpholine with 2-methylpiperidine and keeping other conditions unchanged3Yellow solid, yield 80%. Compound I3Identified as 4- [2- (2-methylpiperidine) ethoxy]-1-azabenzanthrone.
ESI-MS：373.2[M+H]+。
1H-NMR(300MHz,CDCl3,ppm),δH 8.96(d,J＝6Hz,1H),8.82(d,J＝3Hz,1H),8.69(d,J＝6Hz,1H),8.48(d,J＝3H,1H),8.10(d,J＝3Hz,1H),7.84(t,J＝4.5Hz,1H),7.69(t,J＝4.5Hz,1H),7.23(d,J＝3Hz,1H),4.43(t,J＝3Hz,2H),3.32(d,J＝3Hz,1H),3.06(t,J＝3Hz,2H),2.53(t,J＝6Hz,J＝9Hz,2H),1.72(t,J＝6Hz,J＝9Hz,6H),1.25(d,3H).
Example 4: 4- [2- (4-Hydroxyethylpiperazine) ethoxy]-1-azabenzanthrone (I)4) Synthesis of (2)
The reaction formula is as follows:
Figure BDA0002594813190000051
reference Compound I1By the preparation of 4-hydroxyethyl piperazineReplacing morpholine with oxazine, and obtaining the target compound I under the same conditions4Yellow solid, yield 85%. Compound I4Identified as 4- [2- (4-hydroxyethylpiperazine) ethoxy]-1-azabenzanthrone.
ESI-MS：404.3[M+H]+。
1H-NMR(300MHz,CDCl3,ppm),δH 8.94(d,J＝6Hz,1H),8.81(d,J＝6Hz,1H),8.67(d,J＝6Hz,1H),8.46(d,J＝9Hz,1H),8.08(d,J＝6Hz,1H),7.81(t,J＝6Hz,1H),7.67(t,J＝6Hz,1H),7.20(d,J＝9Hz,1H),4.44(t,J＝6Hz,2H),3.65(t,J＝6Hz,2H),3.04(t,J＝6Hz,2H),2.74(s,8H),2.59(t,J＝6Hz,2H).
Example 5: 4- [ (3-morpholine) propoxy group]-1-azabenzanthrone (I)5) Synthesis of (2)
The reaction formula is as follows:
Figure BDA0002594813190000052
reference Compound I1The 1, 3-dibromopropane is used for replacing the compound 1, 2-dibromoethane, and other conditions are not changed to prepare the target compound I5Yellow solid, yield 55%. Compound I5Identified as 4- [ (3-morpholine) propoxy group]-1-azabenzanthrone.
ESI-MS：375.2.[M+H]+。
1H-NMR(300MHz,CDCl3,ppm),δH 8.95(d,J＝9Hz,1H),8.80(d,J＝6Hz,1H),8.66(d,J＝6Hz,1H),8.47(d,J＝9Hz,1H),8.08(d,J＝6Hz,1H),7.83(t,J＝7.5Hz,1H),7.69(t,J＝7.5Hz,1H),7.20(d,J＝6Hz,1H),4.8(t,J＝6Hz,2H),3.79(t,J＝4.5Hz,4H),2.68(t,J＝7.5Hz,2H),2.55(t,J＝4.5Hz,4H),2.21(q,J＝7.5Hz,2H).
Example 6: 4- [3- (2-methylpiperidine) propoxy group]-1-azabenzanthrone (I)6) Synthesis of (2)
The reaction formula is as follows:
Figure BDA0002594813190000061
reference Compound I1The target compound I is prepared by replacing morpholine with 2-methylpiperidine and replacing 1, 2-dibromoethane with 1, 3-dibromopropane, and keeping other conditions unchanged6Yellow solid, 73% yield. Compound I6Identified as 4- [3- (2-methylpiperidine) propoxy group]-1-azabenzanthrone.
ESI-MS：387.1[M+H]+。
1H-NMR(300MHz,CDCl3,ppm),δH 8.80(t,J＝7.5Hz,2H),8.50(d,J＝9Hz,1H),8.27(d,J＝9Hz,1H),8.03(d,J＝6Hz,1H),7.88(t,J＝7.5Hz,1H),7.73(t,J＝7.5Hz,1H),7.42(d,J＝6Hz,1H),4.36(s,2H),2.69(br,3H),2.10(br,2H),1.62(br,4H),1.32(br,4H),1.10(d,3H).
Example 7: 4- [4- (2-methylpiperidine) butoxy]-1-azabenzanthrone (I)7) Synthesis of (2)
The reaction formula is as follows:
Figure BDA0002594813190000062
reference Compound I1The target compound I is prepared by replacing morpholine with 2-methylpiperidine and replacing 1, 2-dibromoethane with 1, 4-dibromobutane under the same conditions7Yellow solid, yield 11%. Compound I7Identified as 4- [4- (2-methylpiperidine) butoxy]-1-azabenzanthrone.
ESI-MS：401.1[M+H]+。
1H-NMR(300MHz,CDCl3,ppm),δH 8.95(d,J＝6Hz,1H),8.79(d,J＝6Hz,1H),8.66(d,J＝6Hz,1H),8.47(d,J＝7.5Hz,1H),8.10(d,J＝7.5Hz,1H),7.83(t,J＝7.5Hz,1H),7.69(t,J＝7.5Hz,1H),7.18(d,J＝6Hz,1H),4.35(t,J＝6Hz,2H),3.86(t,J＝6Hz,2H),2.14(t,J＝7.5Hz,3H),1.92(t,J＝6Hz,2H),1.32(t,11H).
Example 8: 4- [ (4-morpholine) butoxy group]-1-azabenzanthrone (I)8) Synthesis of (2)
The reaction formula is as follows:
Figure BDA0002594813190000063
reference Compound I1The 1, 4-dibromobutane is used for replacing the 1, 2-dibromoethane of the compound, and other conditions are not changed to prepare the target compound I8Yellow solid, yield 49%. Compound I8Identified as 4- [ (4-morpholine) butoxy]-1-azabenzanthrone.
ESI-MS：389.2[M+H]+。
1H-NMR(300MHz,CDCl3,ppm),δH 8.93(d,J＝6Hz,1H),8.78(d,J＝6Hz,1H),8.64(d,J＝6Hz,1H),8.44(d,J＝6Hz,1H),7.93(t,J＝6Hz,1H),7.82(t,J＝7.5Hz,1H),7.67(d,J＝7.5Hz,1H),7.37(d,J＝9Hz,1H),4.05(t,J＝6Hz,2H),3.33(t,J＝3Hz,4H),2.80(t,J＝7.5Hz,2H),2.04(t,J＝6Hz,4H),1.65(m,2H),1.27(m,2H).
Example 9: 4- [ (4-isopropylamino) butoxy]-1-azabenzanthrone (I)9) Synthesis of (2)
The reaction formula is as follows:
Figure BDA0002594813190000071
reference Compound I1The target compound I is prepared by replacing morpholine with 4-isopropylamino and replacing compound 1, 2-dibromoethane with 1, 4-dibromobutane without changing other conditions9Yellow solid, yield 19%. Compound I9Identified as 4- [ (4-isopropylamino) butoxy]-1-azabenzanthrone.
ESI-MS：361.3[M+H]+。
1H-NMR(300MHz,CDCl3,ppm),δH 8.94(d,J＝6Hz,1H),8.77(d,J＝6Hz,1H),8.65(d,J＝9Hz,1H),8.45(d,J＝6Hz,1H),8.08(d,J＝6Hz,1H),7.81(t,J＝7.5Hz,1H),7.67(t,J＝7.5Hz,1H),7.17(d,J＝9Hz,1H),4.34(s,2H),2.98(m,1H),2.48(t,J＝6Hz,2H),1.91(m,4H),1.28(s,6H).
Practice ofExample 10: 4- [4- (4-methylpiperazine) butoxy group]-1-azabenzanthrone (I)10) Synthesis of (2)
The reaction formula is as follows:
Figure BDA0002594813190000072
reference Compound I1The target compound I is prepared by replacing morpholine with 4-methylpiperazine and replacing 1, 2-dibromoethane with 1, 4-dibromobutane under the same conditions10Yellow solid, yield 12%. Compound I10Identified as 4- [4- (4-methylpiperazine) butoxy]-1-azabenzanthrone.
ESI-MS：402.3[M+H]+。
1H-NMR(300MHz,CDCl3,ppm),δH 8.94(d,J＝6Hz,1H),8.78(d,J＝9Hz,1H),8.64(d,J＝6Hz,1H),8.46(d,J＝9Hz,1H),8.08(d,J＝6Hz,1H),7.83(t,J＝7.5Hz,1H),7.68(t,J＝7.5Hz,1H),7.16(d,J＝6Hz,1H),4.34(t,J＝6Hz,2H),3.85(t,J＝6Hz,2H),2.12(m,J＝6Hz,2H),1.93(m,J＝6Hz,2H),1.71(br,3H),1.31(m,8H).
Example 11: 4- [4- (4-Hydroxyethylpiperazine) butoxy group]-1-azabenzanthrone (I)11) Synthesis of (2)
The reaction formula is as follows:
Figure BDA0002594813190000081
reference Compound I1The target compound I is prepared by replacing morpholine with 4-hydroxyethyl piperazinyl and replacing 1, 4-dibromobutane with 1, 2-dibromoethane under the same conditions11Yellow solid, yield 11%. Compound I11Identified as 4- [4- (4-hydroxyethylpiperazine) butoxy]-1-azabenzanthrone.
ESI-MS：432.2[M+H]+。
1H-NMR(300MHz,CDCl3,ppm),δH 8.99(d,J＝6Hz,1H),8.81(d,J＝6Hz,1H),8.68(d,J＝6Hz,1H),8.48(d,J＝6Hz,1H),8.13(d,J＝6Hz,1H),7.85(t,J＝7.5Hz,1H),7.70(t,J＝7.5Hz,1H),7.21(d,J＝6Hz,1H),4.38(t,J＝4.5Hz,2H),3.87(t,J＝4.5Hz,2H),2.15(t,J＝4.5Hz,2H),1.94(t,J＝4.5Hz,2H),1.38(m,12H).
Example 12: 4-piperazine-1-azabenzanthrone (Compound I)12) Synthesis of (2)
The reaction formula is as follows:
Figure BDA0002594813190000082
reference Compound I1The preparation method takes 4- (2-bromoethoxy) -1-azabenzanthrone as a raw material, replaces morpholine by piperazine and does not change other conditions to prepare a target compound I12Yellow solid, yield 12%. Compound I12Identified as 4-piperazine-1-azabenzanthrone.
ESI-MS：316.1[M+H]+。
1H-NMR(300MHz,CDCl3,ppm),δH 8.93(d,J＝9Hz,1H),8.77(d,J＝9Hz,1H),8.63(d,J＝6Hz,1H),8.44(d,J＝9Hz,1H),7.93(d,J＝6Hz,1H),7.81(t,J＝7.5Hz,1H),7.66(t,J＝7.5Hz,1H),7.34(d,J＝9Hz,1H),3.32(t,J＝4.5Hz,4H),3.23(t,J＝3Hz,4H),1.27(s,1H).
TABLE 1 Compound I1-I12Substituent(s) of
Figure BDA0002594813190000083
Figure BDA0002594813190000091
Example 13: pharmacological experiment
The invention adopts a tetramethyl triazole blue colorimetric method (MTT method) to carry out an antitumor activity test on the oxidized iso-aporphine alkaloid derivative, uses oxidized iso-aporphine (Oxo) and adriamycin (Dox) as positive contrast drugs, and tests the inhibitory activity of a target compound and the positive contrast drugs on five cancer cell strains (lung cancer cell strain A549, liver cancer cell HepG-2, human breast cancer cell strain McF-7, MDA-MB-231 and adriamycin-resistant cell strain McF-7/ADR).
The instrument comprises the following steps: superclean bench (SW-CJ-1FD, AIRTECH, Sujing Antai), constant temperature CO2Incubator (3111, Thermo, usa), inverted biomicroscope (IX71, OLYMPUS, japan), enzyme linked immunosorbent assay (Model680, BIO-RAD, usa), shaker (Kylin-bell lab Instruments), autoclave (yxo. sg41.280, shanghai hua line), centrifuge (SIGMA).
Reagent: DMEM (Kayji), RPMI-1640 (Kayji), fetal bovine serum (GIBCO), trypsin (SIGMA), DMSO (SIGMA).
Cell lines: human non-small cell lung cancer cell strain A549, liver cancer cell HepG-2, human breast cancer cell strains McF-7 and MDA-MB-231, and adriamycin-resistant cell strain McF-7/ADR (all purchased from Jiangsu Kai Biotechnology GmbH). DMEM culture medium is used for human non-small cell lung cancer cell strain A549, liver cancer cell HepG-2, human breast cancer cell strain McF-7 and MDA-MB-231, and RPMI-1640 culture medium is used for adriamycin-resistant cell strain McF-7/ADR.
Test compounds: compound I1-I12Oxidized isoaporphine and adriamycin DMSO are respectively prepared into mother liquor with the concentration of 10mM, and then are diluted into serial concentrations by DMEM or RPMI-1640 culture solution.
The method comprises the following steps: recovering the frozen cell strain, and placing the cell strain at the constant temperature of 37 ℃ in CO2Culturing in an incubator, changing the culture medium once every day, and paving when the culture medium is in an exponential growth phase and is in a good state. Adding 1mL of 0.25% trypsin digestive juice, digesting for 1-2min, observing cell state under microscope, removing digestive juice when adherent cells become round and shrink, adding 1-2mL of DMEM or RPMI-1640 medium containing 10% fetal calf serum to make cell suspension, counting cells, and making into 5 × 10 per well4Counting the number of individual cells and the total number of wells to calculate the amount of cell suspension required, plating the cell suspension on a 96-well plate at 100. mu.L/well, sealing the periphery with PBS, and placing at a constant temperature of 37 ℃ in CO2Culturing in an incubator for 24 h.
Taking the cells in exponential growth phase, pouring DMEWashing with PBS once in M/RPMI-1640 culture solution, adding 1mL of 0.25% trypsin digestion solution, digesting for 1-2min, adding 1mL of DMEM culture medium containing 10% fetal calf serum or RPMI-1640 culture solution, and making into the final product with density of 5 × 104one/mL cell suspension, inoculated in a 24-well plate (500. mu.L/well), incubated with CO2Culturing in an incubator for 24 h. Test compounds were added and incubated for 48h with DMSO as a blank. MTT reagent was added to 24-well plates (50. mu.L/well) and incubated in an incubator for 4 h. The supernatant was discarded and dissolved by adding DMSO (500. mu.L/well). Measuring absorbance (OD value) at 570nm with microplate reader, and calculating cell inhibition rate and IC of the test compound according to formula50Values (GraphPad Prism 5 software calculation).
Percent cell inhibition (blank average OD value-drug average OD value)/blank average OD value × 100%
TABLE 2 antiproliferative effect of test compounds on human tumor cell lines
Figure BDA0002594813190000101
As can be seen from Table 2, Compound I1Compound I12The inhibition activity to tumor cells is obviously better than that of oxidized isoaporphine, the inhibition activity to different tumor cells has certain selectivity, and the inhibition activity to human breast cancer cells McF-7 is better than that to human lung cancer cells A549, human liver cancer cells Hep-G2, human breast cancer cells MDA-MB-231 and adriamycin-resistant cell strains McF-7/ADR.
The biological activity of the compounds decreases with increasing carbon chain length, when n is 2 (compound I)1-I4) Shows better biological activity, compound I3(IC501.32-7.64 μ M) showed the most prominent inhibitory activity against tumor cells. The 4-position substituent on the anthrone ring of the compound has obvious influence on the cytotoxic activity of the compound, wherein the activity of the substitution with the methylpiperazine ring is optimal (I)3、I6、I7)。

Claims (6)

1. An oxidized isoaporphine derivative represented by formula I:
Figure FDA0003604001050000011
wherein R is as
Figure FDA0003604001050000012
A is selected from oxygen or a bond, n is an integer of 0 to 4, R1Is selected from
Figure FDA0003604001050000013
Figure FDA0003604001050000014
-NR2R3；R2Selected from H, R3A linear or branched alkyl selected from C1-C3; except that A is selected from oxygen, n is 2, 3, and R is1Is selected from
Figure FDA0003604001050000015
The case (1).
2. The oxoisoaporphine derivative according to claim 1, wherein A is selected from the group consisting of oxygen, n is an integer of 2 to 4, and R is1Is selected from
Figure FDA0003604001050000016
But not including n 2, 3, R1Is selected from
Figure FDA0003604001050000017
Or A is selected from a bond, n ═ 0, and R1Is selected from
Figure FDA0003604001050000018
The case (1).
3. Oxidised isoaporphine derivatives according to claim 2, characterized in that a is selected from the group consisting of oxygen, n-2, R1Is selected from
Figure FDA0003604001050000019
4. Oxidized isoaporphine derivatives according to claim 1, characterized in that they are selected from:
Figure FDA00036040010500000110
5. use of the oxidized isoaporphine derivative according to any one of claims 1 to 4 for the preparation of an antitumor medicament.
6. The use according to claim 5, wherein said tumor is lung cancer, liver cancer, breast cancer.
CN202010706122.8A 2020-07-21 2020-07-21 Oxidized isoaporphine alkaloid derivative and application thereof Active CN111825615B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010706122.8A CN111825615B (en) 2020-07-21 2020-07-21 Oxidized isoaporphine alkaloid derivative and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010706122.8A CN111825615B (en) 2020-07-21 2020-07-21 Oxidized isoaporphine alkaloid derivative and application thereof

Publications (2)

Publication Number Publication Date
CN111825615A CN111825615A (en) 2020-10-27
CN111825615B true CN111825615B (en) 2022-06-10

Family

ID=72923857

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010706122.8A Active CN111825615B (en) 2020-07-21 2020-07-21 Oxidized isoaporphine alkaloid derivative and application thereof

Country Status (1)

Country Link
CN (1) CN111825615B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113264884B (en) * 2021-05-17 2022-10-14 中国药科大学 Oxidized isoaporphine alkaloid derivative and preparation method and application thereof
CN114349700B (en) * 2022-01-21 2023-02-14 中国药科大学 Oxidized isoaporphine alkaloid derivative, preparation method and anti-depression application thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
10-取代1-氮杂苯并蒽酮衍生物的抗肿瘤和抗菌活性研究;覃江克等;《华西药学杂志》;20141231;第29卷(第5期);第522-524页 *
3D-QSAR studies of azaoxoisoaporphine, oxoaporphine, and oxoisoaporphine derivatives as anti-AChE and anti-AD agents by the CoMFA method;Shi-Liang Huang等;《Journal of Molecular Graphics and Modelling》;20131231;第41卷;第61-67页 *
Syntheses and characterization of novel oxoisoaporphine derivatives as dual inhibitors for cholinesterases and amyloid beta aggregation;Zhi-Shu Huang等;《European Journal of Medicinal Chemistry》;20111231;第46卷;第1572-1581页 *

Also Published As

Publication number Publication date
CN111825615A (en) 2020-10-27

Similar Documents

Publication Publication Date Title
CN111825615B (en) Oxidized isoaporphine alkaloid derivative and application thereof
DK2562172T3 (en) Sphaelactonderivater, pharmaceutical compositions thereof, methods of preparation and uses
CN113173857A (en) Cannabidiol derivative and preparation method and application thereof
CN109970679B (en) Paeonol thiazole derivative and preparation method and application thereof
CN115286633A (en) Synthesis of targeting protein chimera with antitumor activity and application of targeting protein chimera as antitumor drug
CN112047880B (en) Azaflavone derivatives and application thereof as antitumor drugs
Gu et al. Novel Synthetic Route to α‐Aminophosphonates Containing Benzothiazole Moiety
CN110156817B (en) Anti-tumor derivative of bi-evodiamine molecule and preparation and application thereof
Li et al. Synthesis and Anti‐tumor Evaluation of Novel C‐37 Modified Derivatives of Gambogic Acid
CN113717138B (en) Nitrogen mustard chromone derivatives and application thereof
CN108276424B (en) Plectranthin type kaurane diterpene assembled nitrogen mustard derivative and preparation method and application thereof
CN111892537B (en) Aporphine alkaloid derivative and preparation method and application thereof
CN106565755B (en) Using 1- pyridine -6- methoxy-p-carbolines as copper nitrate (II) chelate and its synthetic method of ligand and application
CN112961096B (en) Chalcone tryptophan derivatives with cisplatin nephrotoxicity and antitumor activity
CN111675710B (en) Preparation method of duloxetine
CN111004145B (en) Chiral optical amide substituted alpha, beta-diamino acid derivative and preparation method and application thereof
CN113880855A (en) Preparation of 9-fluoro camptothecin derivative and application of 9-fluoro camptothecin derivative in anti-tumor aspect
CN112500412A (en) Penamine A alkaloid structure simplification compound and application thereof
CN106543155B (en) Chalcone and flavonoid derivative as aurora kinase inhibitor
US9758503B1 (en) Coumarin-gossypol derivatives with antitumor activities and a method of preparing the same
CN113563330B (en) 3-position derivative of beta-carbopol as well as preparation method and application thereof
CN113563331B (en) Nitrogen mustard beta-carbopol derivative and preparation method and application thereof
CN115433200B (en) Tetracyclic compound containing chroman-4-one structure, synthesis method and application
CN103044423B (en) Substituted pyridine-2-ketone compounds and preparation method thereof
CN113788809B (en) 3-site mosaic nitrogen mustard derivative of chromone and application

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant